AtriCure endures continued income losses for Q3
AtriCure, a developer of cardiac surgical ablation systems, has reported a rise in net losses and a lowering of revenues for the 2009 third quarter compared with the previous year-ago quarter.
Net losses for the 2009 third quarter rose to $4.7 million, compared with $1.77 million in the 2008 third quarter, according to the West Chester, Ohio-based company.
Revenues for the third quarter of 2009 were $13.3 million, a 10.3 percent decrease over third quarter 2008 revenues of $14.8 million, AtriCure said. Revenues from open-heart products for the third quarter of 2009 were $6.5 million compared with $6.7 million for the third quarter of 2008. Revenues from domestic minimally invasive products declined from $5.7 million for the third quarter of 2008 to $4.2 million for the third quarter of 2009.
Operating expenses for the third quarter of 2009 were $14.4 million compared with $13.2 million for the third quarter of 2008.
Net losses for the 2009 third quarter rose to $4.7 million, compared with $1.77 million in the 2008 third quarter, according to the West Chester, Ohio-based company.
Revenues for the third quarter of 2009 were $13.3 million, a 10.3 percent decrease over third quarter 2008 revenues of $14.8 million, AtriCure said. Revenues from open-heart products for the third quarter of 2009 were $6.5 million compared with $6.7 million for the third quarter of 2008. Revenues from domestic minimally invasive products declined from $5.7 million for the third quarter of 2008 to $4.2 million for the third quarter of 2009.
Operating expenses for the third quarter of 2009 were $14.4 million compared with $13.2 million for the third quarter of 2008.